https://ascopost.com/news/november-2024/valemetostat-in-relapsed-or-refractory-non-hodgkin-lymphoma/
Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma - The ASCO Post
In a phase I study reported in The Lancet Oncology, Maruyama et al reported on the role of a novel dual inhibitor of EZH2 and EZH1, valemetostat, in patients...
non hodgkin lymphomathe asco postvalemetostatrelapsedrefractory